Clinical Study on The Preventive Effect of Zoledronic Acid on The Bone Metastasis in Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 MAIMAITIMING Adilijiang ¹ , GUORui ² ,  AISIMUTULA Dilimulati ¹ , LUANMei-xiang ¹

1. Department of Breast Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomous Region, China;
2. The First Department of Surgery, Xinjiang Hami Central Hospital, Hami 839000, Xinjiang Uygur Autonomous Region, China;

Corresponding author：

AISIMUTULA Dilimulati, Email: 2499156828@qq.com

Keywords：

Zoledronic acid; Breast cancer; Bone metastases; Prevention

DOI：

10.7507/1007-9424.20140167

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the preventive effect of zoledronic acid on the bone metastases of breast cancer. Methods Four hundred and eighteen female patients with infiltrating ductal carcinoma who were underwent surgery in The First Affiliated Hospital of Xinjiang Medical University from Jan. 2006 to Dec. 2009 were collected and divided into 2 group, patients of prevention group accepted the preventive remedy of zoledronic acid(n=216), but patients of control group didn't accept(n=202). Comparison of incidence of bone metastases and recurrence was performed. Results There were 37(17.13%) patients suffered bone metastases in prevention group and 73(36.14%) patients in control group, so the incidence of bone metastases was higher in control group(χ²=19.45, P<0.05). But there were no significant difference on incidence of pulmonary metastasis, liver metastases, other parts of metastases, multiple organ metastases, and recurrence(P>0.05). Conclusion Zoledronic acid could significantly reduce the incidence of bone metastases for patients with breast cancer, who underwent chemotherapy of conventional dose after operation, and it can effectively improve the prognosis of patients with breast cancer.

Citation： MAIMAITIMING Adilijiang, GUORui, AISIMUTULA Dilimulati, LUANMei-xiang. Clinical Study on The Preventive Effect of Zoledronic Acid on The Bone Metastasis in Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(6): 698-701. doi: 10.7507/1007-9424.20140167 Copy

1.	Siegel R, Naishadham D, Jemal A.Cancer statistics, 2013[J].CA Cancer J Clin, 2013, 63(1):11-30.
2.	Coleman RE, Rubens RD.The clinical course of bone metastases from breast cancer[J].Br J Cancer, 1987, 55(1):61-66.
3.	Singletary SE, Walsh G, Vauthey JN, et al.A role for curative surgery in the treatment of selected patients with metastatic breast cancer[J].Oncologist, 2003, 8(3):241-251.
4.	Mundy GR.Metastasis to bone:causes, consequences and therapeutic opportunities[J].Nat Rev Cancer, 2002, 2(8):584-593.
5.	邵志敏,沈镇宙,徐兵河,等.乳腺肿瘤学[M].上海:复旦大学出版社, 2013:777-784.
6.	Mansi JL, Gogas H, Bliss JM, et al.Outcome of primary-breastcancer patients with micrometastases:a long-term follow-up study[J].Lancet, 1999, 354(9174):197-202.
7.	Roodman GD.Mechanisms of bone metastasis[J].N Engl J Med, 2004, 350(16):1655-1664.
8.	Coleman RE.Metastatic bone disease:clinical features, pathophysiology and treatment strategies[J].Cancer Treat Rev, 2001, 27(3):165-176.
9.	Schenk R, Eggli P, Fleisch H, et al.Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat[J].Calcif Tissue Int, 1986, 38(6):342-349.
10.	Russell RG, Xia Z, Dunford JE, et al.Bisphosphonates:an update on mechanisms of action and how these relate to clinical efficacy[J].Ann N Y Acad Sci, 2007, 1117(11):209-257.
11.	US Preventive Services Task Force.Screening for breast cancer:U.S.Preventive Services Task Force recommendation statement[J].Ann Intern Med, 2009, 151(10):716-726.
12.	Li GL, Chen WQ.Representativeness of population-based cancer registration in China-comparison of urban and rural areas[J].Asian Pac J Cancer Prev, 2009, 10(4):559-564.
13.	Goldhirsch A, Wood WC, Coates AS, et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol, 2011, 22(8):1736-1747.
14.	孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生出版社, 2007:920-921.
15.	Moreau J, Anderson KM, Mauney JR, et al.Studies of osteotropism on both sides of the breast cancer-bone interaction[J].Ann N Y Acad Sci, 2007, 1117(11):328-344.
16.	Paget S.The distribution of secondary growths in cancer of the breast.1889[J].Cancer Metastasis Rev, 1989, 8(2):98-101.
17.	Cawthorn TR, Amir E, Broom R, et al.Mechanisms and pathways of bone metastasis:challenges and pitfalls of performing molecular research on patient samples[J].Clin Exp Metastasis, 2009, 26(8):935-943.
18.	Psaila B, Lyden D.The metastatic niche:adapting the foreign soil[J].Nat Rev Cancer, 2009, 9(4):285-293.
19.	Gnant M, Mlineritsch B, Stoeger H, et al.Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with earlystage breast cancer:62-month follow-up from the ABCSG-12 randomised trial[J].Lancet Oncol, 2011, 12(7):631-641.
20.	Bundred NJ, Campbell ID, Davidson N, et al.Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole:ZO-FAST Study results[J].Cancer, 2008, 112(5):1001-1010.
21.	AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal>5 years[J].Oncology (Williston Park), 2011, 25(12):1212-1213.
22.	Harris JR, Lippman ME, Morrow M著.王永胜,吴炅,于金明,等译[M].第4版.济南:山东科学技术出版社, 2012:1543-1555.
23.	洪婷婷,华东.含氮双磷酸盐的抗肿瘤作用[J].国际肿瘤学杂志, 2011, 38(4):257-258.

1. Siegel R, Naishadham D, Jemal A.Cancer statistics, 2013[J].CA Cancer J Clin, 2013, 63(1):11-30.
2. Coleman RE, Rubens RD.The clinical course of bone metastases from breast cancer[J].Br J Cancer, 1987, 55(1):61-66.
3. Singletary SE, Walsh G, Vauthey JN, et al.A role for curative surgery in the treatment of selected patients with metastatic breast cancer[J].Oncologist, 2003, 8(3):241-251.
4. Mundy GR.Metastasis to bone:causes, consequences and therapeutic opportunities[J].Nat Rev Cancer, 2002, 2(8):584-593.
5. 邵志敏,沈镇宙,徐兵河,等.乳腺肿瘤学[M].上海:复旦大学出版社, 2013:777-784.
6. Mansi JL, Gogas H, Bliss JM, et al.Outcome of primary-breastcancer patients with micrometastases:a long-term follow-up study[J].Lancet, 1999, 354(9174):197-202.
7. Roodman GD.Mechanisms of bone metastasis[J].N Engl J Med, 2004, 350(16):1655-1664.
8. Coleman RE.Metastatic bone disease:clinical features, pathophysiology and treatment strategies[J].Cancer Treat Rev, 2001, 27(3):165-176.
9. Schenk R, Eggli P, Fleisch H, et al.Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat[J].Calcif Tissue Int, 1986, 38(6):342-349.
10. Russell RG, Xia Z, Dunford JE, et al.Bisphosphonates:an update on mechanisms of action and how these relate to clinical efficacy[J].Ann N Y Acad Sci, 2007, 1117(11):209-257.
11. US Preventive Services Task Force.Screening for breast cancer:U.S.Preventive Services Task Force recommendation statement[J].Ann Intern Med, 2009, 151(10):716-726.
12. Li GL, Chen WQ.Representativeness of population-based cancer registration in China-comparison of urban and rural areas[J].Asian Pac J Cancer Prev, 2009, 10(4):559-564.
13. Goldhirsch A, Wood WC, Coates AS, et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol, 2011, 22(8):1736-1747.
14. 孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生出版社, 2007:920-921.
15. Moreau J, Anderson KM, Mauney JR, et al.Studies of osteotropism on both sides of the breast cancer-bone interaction[J].Ann N Y Acad Sci, 2007, 1117(11):328-344.
16. Paget S.The distribution of secondary growths in cancer of the breast.1889[J].Cancer Metastasis Rev, 1989, 8(2):98-101.
17. Cawthorn TR, Amir E, Broom R, et al.Mechanisms and pathways of bone metastasis:challenges and pitfalls of performing molecular research on patient samples[J].Clin Exp Metastasis, 2009, 26(8):935-943.
18. Psaila B, Lyden D.The metastatic niche:adapting the foreign soil[J].Nat Rev Cancer, 2009, 9(4):285-293.
19. Gnant M, Mlineritsch B, Stoeger H, et al.Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with earlystage breast cancer:62-month follow-up from the ABCSG-12 randomised trial[J].Lancet Oncol, 2011, 12(7):631-641.
20. Bundred NJ, Campbell ID, Davidson N, et al.Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole:ZO-FAST Study results[J].Cancer, 2008, 112(5):1001-1010.
21. AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal>5 years[J].Oncology (Williston Park), 2011, 25(12):1212-1213.
22. Harris JR, Lippman ME, Morrow M著.王永胜,吴炅,于金明,等译[M].第4版.济南:山东科学技术出版社, 2012:1543-1555.
23. 洪婷婷,华东.含氮双磷酸盐的抗肿瘤作用[J].国际肿瘤学杂志, 2011, 38(4):257-258.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Clinical Study on The Preventive Effect of Zoledronic Acid on The Bone Metastasis in Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content